Janet Wiegand
Scientific Laboratory Manager
Publications
2020
DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas.
Journal of hematology & oncology.
13(1)
[DOI] 10.1186/s13045-020-00928-9.
[PMID] 32677976.
2020
Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity.
Nature communications.
11(1)
[DOI] 10.1038/s41467-020-15838-0.
[PMID] 32332723.
2019
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity.
Nature medicine.
25(12):1938-1947
[DOI] 10.1038/s41591-019-0668-z.
[PMID] 31792461.
2015
Metabolically programmed iron chelators.
Bioorganic & medicinal chemistry.
23(17):5954-71
[DOI] 10.1016/j.bmc.2015.06.059.
[PMID] 26231739.
2014
Desferrithiocin: a search for clinically effective iron chelators.
Journal of medicinal chemistry.
57(22):9259-91
[DOI] 10.1021/jm500828f.
[PMID] 25207964.
2012
Substituent effects on desferrithiocin and desferrithiocin analogue iron-clearing and toxicity profiles.
Journal of medicinal chemistry.
55(16):7090-103
[DOI] 10.1021/jm300509y.
[PMID] 22889170.
2011
Desferrithiocin analogue iron chelators: iron clearing efficiency, tissue distribution, and renal toxicity.
Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine.
24(2):239-58
[DOI] 10.1007/s10534-010-9389-y.
[PMID] 21103911.
2010
The impact of polyether chain length on the iron clearing efficiency and physiochemical properties of desferrithiocin analogues.
Journal of medicinal chemistry.
53(7):2843-53
[DOI] 10.1021/jm9018146.
[PMID] 20232803.
2009
Desferrithiocin analogue uranium decorporation agents.
International journal of radiation biology.
85(4):348-61
[DOI] 10.1080/09553000902781089.
[PMID] 19399680.
2009
Vibriobactin antibodies: a vaccine strategy.
Journal of medicinal chemistry.
52(12):3801-13
[DOI] 10.1021/jm900119q.
[PMID] 19492834.
2008
Desferrithiocin analogues and nephrotoxicity.
Journal of medicinal chemistry.
51(19):5993-6004
[DOI] 10.1021/jm8003398.
[PMID] 18788724.
2008
Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.
Journal of medicinal chemistry.
51(13):3913-23
[DOI] 10.1021/jm800154m.
[PMID] 18533709.
2008
Impact of laughter on air trapping in severe chronic obstructive lung disease.
International journal of chronic obstructive pulmonary disease.
3(1):185-92
[PMID] 18488442.
View on:
PubMed
2007
Impact of the 3,6,9-trioxadecyloxy group on desazadesferrithiocin analogue iron clearance and organ distribution.
Journal of medicinal chemistry.
50(14):3302-13
[PMID] 17564424.
View on:
PubMed
2006
The design, synthesis, and evaluation of organ-specific iron chelators.
Journal of medicinal chemistry.
49(24):7032-43
[PMID] 17125256.
View on:
PubMed
2006
(S)-4,5-dihydro-2-(2-hydroxy-4-hydroxyphenyl)-4-methyl-4-thiazolecarboxylic acid polyethers: a solution to nephrotoxicity.
Journal of medicinal chemistry.
49(9):2772-83
[PMID] 16640338.
View on:
PubMed
2005
Partition-variant desferrithiocin analogues: organ targeting and increased iron clearance.
Journal of medicinal chemistry.
48(3):821-31
[PMID] 15689166.
View on:
PubMed
2005
Polyamine-vectored iron chelators: the role of charge.
Journal of medicinal chemistry.
48(12):4120-37
[PMID] 15943485.
View on:
PubMed
2004
Comparison of iron chelator efficacy in iron-overloaded beagle dogs and monkeys (Cebus apella).
Comparative medicine.
54(6):664-72
[PMID] 15679265.
View on:
PubMed
2003
Desferrithiocin analogue based hexacoordinate iron(III) chelators.
Journal of medicinal chemistry.
46(1):16-24
[PMID] 12502356.
View on:
PubMed
2003
Iron chelation promoted by desazadesferrithiocin analogs: An enantioselective barrier.
Chirality.
15(7):593-9
[PMID] 12840823.
View on:
PubMed
2003
Methoxylation of desazadesferrithiocin analogues: enhanced iron clearing efficiency.
Journal of medicinal chemistry.
46(8):1470-7
[PMID] 12672247.
View on:
PubMed
2003
Prevention of acetic acid-induced colitis by desferrithiocin analogs in a rat model.
Digestive diseases and sciences.
48(2):399-407
[PMID] 12643622.
View on:
PubMed
2002
HBED ligand: preclinical studies of a potential alternative to deferoxamine for treatment of chronic iron overload and acute iron poisoning.
Blood.
99(8):3019-26
[PMID] 11929795.
View on:
PubMed
2002
Structure-activity relationships among desazadesferrithiocin analogues.
Advances in experimental medicine and biology.
509:167-84
[PMID] 12572994.
View on:
PubMed
2001
Control of irritable bowel syndrome with polyamine analogs: a structure-activity study.
Digestive diseases and sciences.
46(12):2615-23
[PMID] 11768250.
View on:
PubMed
2001
Significance of asymmetric sites in choosing siderophores as deferration agents.
Journal of medicinal chemistry.
44(15):2469-78
[PMID] 11448229.
View on:
PubMed
2001
Synthesis and evaluation of hydroxylated polyamine analogues as antiproliferatives.
Journal of medicinal chemistry.
44(15):2451-9
[PMID] 11448227.
View on:
PubMed
2001
Polyamine analogue antidiarrheals: a structure-activity study.
Journal of medicinal chemistry.
44(2):232-44
[PMID] 11170633.
View on:
PubMed
2000
Metabolism and pharmacokinetics of N1,N11-diethylnorspermine in a Cebus apella primate model.
Cancer research.
60(16):4433-9
[PMID] 10969789.
View on:
PubMed
1999
Desazadesmethyldesferrithiocin analogues as orally effective iron chelators.
Journal of medicinal chemistry.
42(1):95-108
[PMID] 9888836.
View on:
PubMed
1999
Effects of C-4 stereochemistry and C-4′ hydroxylation on the iron clearing efficiency and toxicity of desferrithiocin analogues.
Journal of medicinal chemistry.
42(13):2432-40
[PMID] 10395484.
View on:
PubMed
1999
Evaluation of the desferrithiocin pharmacophore as a vector for hydroxamates.
Journal of medicinal chemistry.
42(15):2881-6
[PMID] 10425097.
View on:
PubMed
1999
HBED: the continuing development of a potential alternative to deferoxamine for iron-chelating therapy.
Blood.
93(1):370-5
[PMID] 9864183.
View on:
PubMed
1999
Pharmacokinetics of orally administered desferrithiocin analogs in cebus apella primates.
Drug metabolism and disposition: the biological fate of chemicals.
27(12):1496-8
[PMID] 10570032.
View on:
PubMed
1998
HBED: A potential alternative to deferoxamine for iron-chelating therapy.
Blood.
91(4):1446-52
[PMID] 9454776.
View on:
PubMed
1998
The origin of the differences in (R)- and (S)-desmethyldesferrithiocin. Iron-clearing properties.
Annals of the New York Academy of Sciences.
850:202-16
[PMID] 9668541.
View on:
PubMed
1996
Synthesis and biological evaluation of naphthyldesferrithiocin iron chelators.
Journal of medicinal chemistry.
39(8):1575-81
[PMID] 8648596.
View on:
PubMed
1996
Metabolism and pharmacokinetics of N1,N14-diethylhomospermine.
Drug metabolism and disposition: the biological fate of chemicals.
24(3):334-43
[PMID] 8820425.
View on:
PubMed
1995
Metabolism and pharmacokinetics of N1,N11-diethylnorspermine.
Drug metabolism and disposition: the biological fate of chemicals.
23(10):1117-25
[PMID] 8654201.
View on:
PubMed
1994
An investigation of desferrithiocin metabolism.
Journal of medicinal chemistry.
37(18):2889-95
[PMID] 8071936.
View on:
PubMed
1994
The desferrithiocin pharmacophore.
Journal of medicinal chemistry.
37(10):1411-7
[PMID] 8182699.
View on:
PubMed
1993
A comparative study of the iron-clearing properties of desferrithiocin analogues with desferrioxamine B in a Cebus monkey model.
Blood.
81(8):2166-73
[PMID] 8471775.
View on:
PubMed
1993
A comparison of the iron-clearing properties of parabactin and desferrioxamine.
Blood.
82(8):2552-7
[PMID] 8400302.
View on:
PubMed
1992
A comparison of the iron-clearing properties of 1,2-dimethyl-3-hydroxypyrid-4-one, 1,2-diethyl-3-hydroxypyrid-4-one, and deferoxamine.
Blood.
79(7):1882-90
[PMID] 1558978.
View on:
PubMed
1992
Structural alterations in desferrioxamine compatible with iron clearance in animals.
Journal of medicinal chemistry.
35(25):4739-44
[PMID] 1469701.
View on:
PubMed
1992
Synovial and serum levels of triamcinolone following intra-articular administration of triamcinolone acetonide in the horse.
Journal of veterinary pharmacology and therapeutics.
15(3):240-6
[PMID] 1433486.
View on:
PubMed
1991
Evaluation of desferrithiocin and its synthetic analogues as orally effective iron chelators.
Journal of medicinal chemistry.
34(7):2072-8
[PMID] 2066978.
View on:
PubMed
1991
Synthesis and biological evaluation of hydroxamate-based iron chelators.
Journal of medicinal chemistry.
34(11):3182-7
[PMID] 1956036.
View on:
PubMed
1990
A comparative evaluation of iron clearance models.
Annals of the New York Academy of Sciences.
612:378-93
[PMID] 2127168.
View on:
PubMed
Contact Details
Phones:
- Business:
- (352) 273-7735
Emails:
- Business:
- jwiegand@ufl.edu